IDH1 and astrocytoma (excluding glioblastoma): This study aimed to identify treatment outcomes and prognostic factors for IDH-WT histological grade 2/3 astrocytomas with molecular features of glioblastoma, IDH-wildtype, CNS WHO grade 4, and to capture changing treatment trends.